Robyn T. Domsic, MD, MPH
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Robyn T. Domsic, MD, MPH sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Robyn T. Domsic, MD, MPH: 4 sponsored US clinical trials, 2 recruiting.
Robyn T. Domsic, MD, MPH sponsors 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Systemic Sclerosis (SSc), with 2 trials.
Upper-quartile sponsor footprint
Robyn T. Domsic, MD, MPH sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Intralesional Injection of STS in Treatment of Calcinosis
NCT06672822
The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of Life
NCT06675344
Apollo Device for Fatigue in Systemic Sclerosis
NCT04854850
Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma
NCT02370784
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
Therapeutic Areas
What is open in the Robyn T. Domsic, MD, MPH pipeline
2 recruiting of 4 indexed (50% open); 2 completed (50%).
Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).
Top condition: Systemic Sclerosis (SSc) (2 trials), 3 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Robyn T. Domsic, MD, MPH: open-pipeline peers nationwide
Peers matched on 4 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Robyn T. Domsic, MD, MPH sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
Related
What to do with this Robyn T. Domsic, MD, MPH page
4 registered trials is a research-attention snapshot, not an endorsement of Robyn T. Domsic, MD, MPH or any single study.
- 2 of Robyn T. Domsic, MD, MPH's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Systemic Sclerosis (SSc) is the condition Robyn T. Domsic, MD, MPH studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Systemic Sclerosis (SSc) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Robyn T. Domsic, MD, MPH pipeline card: 4 registered trials from official public datasets.Report a data error.